Designing HIPEC regimens for colon cancer: Is the available evidence being appropriately considered? - 08/09/21
, Oriol Crusellas a, Isabel Ramos a, Kurt Van der Speeten b, c, Pedro Barrios a, Domenico Sabia a
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
The treatment of peritoneal metastases (PM) from colorectal cancer (CRC) has been revolutionized by the availability of cytoreductive surgery (CRS), traditionally coupled with Hyperthermic Intraperitoneal Peroperative Chemotherapy (HIPEC). The impact of HIPEC itself, over the effect of surgery is poorly understood and the presence of various HIPEC regimens for CRC PM complicates objective evaluation. A recent randomized controlled trial (RCT) evaluating one of the CRC HIPEC regimens (30 min of intraperitoneal (IP) oxaliplatin) showed no increase in survival compared to CRS alone.
There is uncertainty regarding the current and future use of HIPEC in CRC PM.
A reevaluation of existing and the publication of new preclinical work is needed, to analyze potential efficacy of alterantive HIPEC regimens. New advanced phase clinical trials should not be started without convincing preclinical and early phase data on new IP chemotherapy regimens.
This review is a critical appraisal of the available preclinical and clinical data to support the design of an alternative HIPEC regimen for CRC focusing on CRC PM specific data. We find that current evidence supports several regimens that have not been tested in prospective clinical trials while the one tested in the PRODIGE-7 RCT has little supportive evidence.
Le texte complet de cet article est disponible en PDF.Plan
| Conflict of interest: No commercial interest and source of any financial or material support. |
|
| Synopsis This manuscript is a review of available animal model-based preclinical and clinical data to support a rational and evidence-based design of a HIPEC regimen for colorectal cancer as an alternative to the 30 min oxaliplatin regimen. |
Vol 3
Article 100019- septembre 2021 Retour au numéro
Article précédent
- Can we improve the classification of ampullary adenocarcinoma? The value of histomolecular classification and clinicopathological features on prognosis
- Paula Muñoz-Muñoz, Irene Carretero, Raquel Arranz, Esther Moreno, Laura Del Campo-Abendea, Ángela Santana, Cristian Perna, Alejandra Caminoa, Javier Zamora, José María Fernández-Cebrián, Alfonso Sanjuanbenito
- Trans-fistula percutaneous endoscopic jejunostomy (TF-PEJ) following a case of emergency pancreaticoduodenectomy
- Nili Gutwetter, Ori Yaslowitz, Shmuel Avital, Ilia Sergeev, Fabiana Benjaminov, Yaron Rudnicki
Bienvenue sur EM-consulte, la référence des professionnels de santé.